Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Angiotensin-(1-7) vs Vesugen
An educational, source-based comparison of Angiotensin-(1-7) and Vesugen — how each peptide works, what it's researched for, and what to know before going deeper.
Counter-regulatory peptide of the renin-angiotensin system.
A heptapeptide of the renin-angiotensin system that acts on Mas receptors. Research demonstrates counter-regulatory effects to angiotensin II, promoting vasodilation, anti-inflammatory signaling, and anti-fibrotic effects in cardiovascular and renal tissues.
- Pulmonary hypertension and fibrosis
- Heart failure with preserved ejection fraction
- Acute lung injury and ARDS
- Diabetic nephropathy
- • Investigational; not FDA-approved.
- • Interaction with ACE inhibitors and ARBs requires careful study design.
A synthetic tripeptide (Lys-Glu-Asp) in the Khavinson bioregulator family. Research indicates modulation of endothelial cell function and vascular wall gene expression, supporting vascular tone and microcirculation.
- Vascular endothelial function
- Microcirculation in aging
- Peripheral vascular disorders
- • Russian-origin research; independent replication limited.
- • Not FDA-approved.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Angiotensin-(1-7) | Angiotensin-(1-7) as a therapeutic in lung disease | American Journal of Respiratory and Critical Care Medicine | 2020 | Demonstrated protective effects in acute lung injury and pulmonary fibrosis models. |
| Angiotensin-(1-7) | Mas receptor activation in cardiovascular protection | Circulation Research | 2018 | Reviewed anti-inflammatory and anti-fibrotic mechanisms in cardiac tissue. |
| Vesugen | Vesugen and vascular endothelial gene expression | Bulletin of Experimental Biology and Medicine | 2014 | Enhanced endothelial nitric oxide synthase expression in vascular tissue models. |
Side-effect & safety grid
- Investigational; not FDA-approved.
- Interaction with ACE inhibitors and ARBs requires careful study design.
- Russian-origin research; independent replication limited.
- Not FDA-approved.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Angiotensin-(1-7) vs Vesugen — Key differences
- Class: Angiotensin-(1-7) is classified as Cardiovascular · Anti-inflammatory, while Vesugen is Vascular · Bioregulator.
- Primary research focus: Angiotensin-(1-7) — pulmonary hypertension and fibrosis; Vesugen — vascular endothelial function.
- Tag: Cardiovascular · Anti-inflammatory vs Vascular · Bioregulator.